Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.
新型低劑量三合一單顆藥丸組合 telmisartan、amlodipine 和 indapamide 在高血壓治療中的療效和安全性:一項隨機、雙盲、主動對照的國際臨床試驗。
Lancet 2024-10-19
Empagliflozin combined with sacubitril/valsartan in hypertensive patients with heart failure: a retrospective study of efficacy and effect on blood pressure variability and cardiac function.
Empagliflozin 與 sacubitril/valsartan 併用於高血壓心衰竭患者的療效及對血壓變異性和心臟功能影響的回顧性研究。
Am J Transl Res 2024-08-08
Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.
尼日利亞低劑量三合一藥丸與標準護理方案在高血壓治療中的比較:一項隨機臨床試驗。
JAMA 2024-08-31
Blood Pressure Reduction and Changes in Antihypertensive Medication Use Among Patients With Hypertension Who Initiated Sodium-Glucose Cotransporter-2 Inhibitors.
使用鈉-葡萄糖共轉運蛋白-2抑制劑的高血壓患者血壓降低及抗高血壓藥物使用變化。
J Clin Hypertens (Greenwich) 2024-10-07
Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
Dapagliflozin 和 linagliptin (AJU-A51) 固定劑量聯合療法在 2 型糖尿病患者中的療效和安全性:一項多中心、隨機、雙盲、平行組、安慰劑對照的第三期研究。
Diabetes Obes Metab 2024-10-08
Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial.
Alogliptin/Metformin 固定劑量聯合片與 Vildagliptin/Metformin 固定劑量聯合片在實際臨床實踐中對 2 型糖尿病患者血糖控制的療效:一項多中心、開放標籤、隨機、平行組、比較試驗。
Metab Syndr Relat Disord 2024-11-01
A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).
一項前瞻性多中心研究評估 Remogliflozin etabonate、Vildagliptin 和 Metformin 固定劑量聯合療法在印度 2 型糖尿病患者中的安全性和有效性 (Triad-RMV)。
Clin Diabetes Endocrinol 2024-12-17
Efficacy of Dapagliflozin and Telmisartan Combination Therapy in Reducing Albuminuria and Inflammatory Markers in Diabetic Nephropathy: A Prospective Observational Study.
Dapagliflozin 與 Telmisartan 組合療法在降低糖尿病腎病患者的白蛋白尿及炎症標記物的療效:一項前瞻性觀察研究。
Curr Vasc Pharmacol 2025-02-14
Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
在印度進行的第三期開放標籤隨機臨床研究:對於使用 metformin 和 glimepiride 控制不佳的 2 型糖尿病患者,dapagliflozin、glimepiride 和延釋型 metformin 固定劑量聯合片劑的療效。
Diabetes Obes Metab 2025-02-14
這項研究評估了dapagliflozin、glimepiride和延釋型美克福的固定劑量聯合療法在印度2型糖尿病患者中的療效與安全性。研究為期最多30週,主要治療階段16週,結果顯示DAPA + GLIM + MET ER組的HbA1c減少顯著高於雙重FDC組(-1.98%對-1.64%)。此外,達到HbA1c低於7.0%的患者比例也較高。兩組的血糖水準均顯著下降,且不良事件發生率相似。結論是DAPA + GLIM + MET ER FDC在改善血糖控制方面更有效,且耐受性良好。
PubMedDOI